# Kevin Outterson

> Kevin Outterson is a grant investor at CARB-X backing Biotechnology. See 34 investments, check sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Fund: [CARB-X](https://shizune.co/investors/profile/carb-x)
- Location: Boston, United States
- Total investments: 34
- Last investment: Jun 2021
- Lead investor: 97%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/kevin-outterson-5068b311/
- X (Twitter): https://twitter.com/koutterson

Kevin Outterson is a grant investor at CARB-X in Boston focused on Biotechnology and Health Care. Kevin Outterson is based out of Boston, Massachusetts, and is the Executive Director of CARB-X and Professor, Boston University of Boston University School of Law. Kevin previously worked at Chatham House as a Visiting Scholar. Kevin Outterson attended the Northwestern University Pritzker School of Law.

## Contacts

5 contacts available for Kevin Outterson: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/kevin-outterson?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 27 | 79% |
| Health Care | 15 | 44% |
| Pharmaceutical | 15 | 44% |
| Medical | 11 | 32% |
| Therapeutics | 8 | 24% |

14 industries tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 19 | 56% |
| Switzerland | 5 | 15% |
| United Kingdom | 2 | 6% |
| India | 1 | 3% |
| Japan | 1 | 3% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BioVersys | Bioversys AG is a biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Their focus is on creating therapies to combat multidrug-resistant (MDR) bacterial infections, a major globalhealth issue. BioVersys’ proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform is designed to identify new treatments by inhibiting bacterial resistance mechanisms, thereby making antibiotics more effective. | $4.4M | Grant | Jun 01, 2021 | http://www.bioversys.com |
| Vedanta Biosciences | Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $5.8M | Grant | Dec 05, 2019 | http://www.vedantabio.com |
| Venatorx Pharmaceuticals | Venatorx Pharmaceuticals is a private company that focuses on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. The company was founded in 2010 and is headquartered in Malvern, Pennsylvania. | $4.1M | Grant | Nov 25, 2019 | https://www.venatorx.com |
| Techulon | Techulon is a biotech firm located in Blacksburg, Virginia. Their headquarters and laboratories are located in the Virginia Tech Corporate Research Center, and their products derive from patents that we license from Virginia Tech. Their main laboratory is outfitted with equipment for the development, manufacture and commercialization ofbiopolymers applicable to research, therapeutics, energy and sustainability. | $785K | Grant | Nov 06, 2019 | http://www.techulon.com |
| BioVersys | Bioversys AG is a biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Their focus is on creating therapies to combat multidrug-resistant (MDR) bacterial infections, a major globalhealth issue. BioVersys’ proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform is designed to identify new treatments by inhibiting bacterial resistance mechanisms, thereby making antibiotics more effective. | $8.9M | Grant | Oct 29, 2019 | http://www.bioversys.com |
| Vaxxilon | Vaxxilon AG is focused on the discovery and development of innovative synthetic carbohydrate vaccines. Headquartered near Basel, Switzerland with research labs in Berlin, the Vaxxilon team is advancing several vaccine candidates for the prevention of major infectious diseases. | $1.4M | Grant | Aug 20, 2019 | http://vaxxilon.com/ |
| Integrated BioTherapeutics | A biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. It antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines and a variety of other product candidates for emerging viruses. | $1.6M | Grant | Jul 01, 2019 | http://www.integratedbiotherapeutics.com |
| Vaxcyte | Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma,Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG). | $1.6M | Grant | Jun 01, 2019 | http://www.vaxcyte.com/ |
| Debiopharm Group | Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. They develop their products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. | $2.1M | Grant | May 14, 2019 | http://www.debiopharm.com/ |
| Recida Therapeutics | Recida Therapeutics is a Biotechnology company. | $4.4M | Grant | Feb 06, 2019 | http://www.recidatherapeutics.com |

10 of 34 investments shown.

## Co-investors
- [Bill & Melinda Gates Foundation](https://shizune.co/investors/profile/bill-melinda-gates-foundation) — VC Fund, 1 deal together
- [Biomedical Advanced Research and Development Authority (BARDA)](https://shizune.co/investors/profile/biomedical-advanced-research-and-development-authority-barda) — VC Fund, 1 deal together
- Department of Health and Social Care (DHSC) — VC Fund, 1 deal together
- [German Federal Ministry of Research, Technology and Space](https://shizune.co/investors/profile/german-federal-ministry-of-education-and-research-bmbf) — VC Fund, 1 deal together
- National Institute of Allergy and Infectious Diseases — VC Fund, 1 deal together
- [Wellcome Trust](https://shizune.co/investors/profile/wellcome-trust) — VC Fund, 1 deal together

## About CARB-X

VC Fund · Boston, United States

Accelerate a diverse portfolio of at least 20 high-quality antibacterial products towards clinical development leveraging $250 million in BARDA funds with matching funds from the Wellcome Trust and the AMR Centre.

3 contacts available at CARB-X.

| Name | Title | Profile |
| --- | --- | --- |
| Diane MacDonald | Chief Operating Officer | https://shizune.co/investors/profile/diane-macdonald-ac8a |
| Kevin Outterson | Executive Director | https://shizune.co/investors/profile/kevin-outterson |
| Richard Alm | Chief Scientific Officer | https://shizune.co/investors/profile/richard-alm-46a6 |

## Similar investors

### Similar stage
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [Wayra](https://shizune.co/investors/profile/wayra) — VC Fund
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund

## FAQ

### What does Kevin Outterson invest in?

Kevin Outterson invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Grant stage. Most of the 34 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Kevin Outterson?

Public channels for Kevin Outterson include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Kevin Outterson last invest?

The most recent investment recorded for Kevin Outterson closed in Jun 2021. Shizune tracks 34 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co